Physician profile
Ashley D Locklear-Batton
NPI 1366882722
$4,287.09
in general payments reported to CMS, 2019-2025
41 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.29 · 2020: $539 · 2021: $708 · 2022: $599 · 2023: $1,120 · 2024: $842 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,392.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $729.34 | 2020-2025 | |
| Novo Nordisk INC | $628.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $452.39 | 2020-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $280.48 | 2020-2025 | |
| Amgen INC. | $224.51 | 2020-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $200.68 | 2020-2022 | |
| Amarin Pharma, INC. | $191.56 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $170.41 | 2019-2025 | Farxiga |
| Sumitomo Pharma America, INC. | $130.91 | 2023-2024 | Gemtesa |
| Abbott Laboratories | $106.32 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $97.49 | 2021-2024 | Jardiance, Mounjaro |
| Merck Sharp & Dohme LLC | $84.97 | 2020-2024 | Capvaxive, Gardasil 9, Gardasil |
| Upsher-Smith Laboratories LLC | $70.36 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.76 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $62.73 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Locklear-Batton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.